Calypso Biotech SA announced today that it has entered a global licensing and collaboration agreement with EA Pharma Co., Ltd. to develop CALY-001, a best-in-class anti-MMP-9 fully human monoclonal antibody.
We run statistic cookies to help us understand how visitors interact with our website by collecting and reporting information anonymously. By continuing to use our website you consent to cookies being used.YesPrivacy policy